Cancer News and Research

Latest Cancer News and Research

CMC hospital Ludhiana upgrades to MLCi2-equipped Elekta Compact linear accelerator

Christian Medical College & Hospital (CMC) Ludhiana is the site of the first Elekta Compact™ linear accelerator in the world to be field-upgraded to an MLCi2-equipped Elekta Compact, completing the transformation in less than a week. MLCi2 shapes treatment beams, enabling doctors to provide more accurate delivery to the target, while limiting radiation exposure to surrounding structures.

From Elekta 11 Jul 2011

Cancer Research UK awards £12 million to 10 exceptional researchers

Cancer Research UK has given a number of prestigious grants to new investigators who are set to become the eminent cancer scientists of the future.

11 Jul 2011

Anavex exercises warrants to raise $1.575 million

Anavex Life Sciences Corp. is pleased to announce that it has raised $1,575,000 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company's lead drug candidate for Alzheimer's disease, to advance other compounds in the Anavex pipeline, and for general corporate purposes.

11 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

Generex announces convertible preferred stock securities purchase agreement

Generex Biotechnology Corporation today announced that it entered into a securities purchase agreement with certain institutional investors on July 8, 2011.

11 Jul 2011

Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line

Sunshine Biopharma Inc., a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.

11 Jul 2011

Nevada District Court rules in favor of PDL over Genentech, Roche lawsuit

PDL BioPharma, Inc. (PDL) announced a favorable ruling today, specifically, that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F. Hoffmann LaRoche, Ltd. in PDL's lawsuit related to the 2003 settlement agreement with Genentech.

11 Jul 2011

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

Micromet, Inc. announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets.

11 Jul 2011

New radiofrequency ablation system for treating spinal tumors

The Orthopedic Clinic and Policlinic at the University Medical Center of Johannes Gutenberg University Mainz (JGU) has recently deployed a new system for the treatment of spinal tumors for the first time.

11 Jul 2011

People with long term debilitating physical illness demonstrate mental resilience

People who have a long term debilitating physical illness demonstrate mental resilience according to Understanding Society, the world's largest longitudinal household study.

11 Jul 2011

Randox launches Lab Tests Blog

Randox Laboratories is excited to announce the launch of its very own online blog - Lab Tests Blog.

From Randox Laboratories Ltd. 11 Jul 2011

Insights into how brain can preserve memory and prevent forgetting

As any student who's had to study for multiple exams can tell you, trying to learn two different sets of facts one after another is challenging. As you study for the physics exam, almost inevitably some of the information for the history exam is forgotten.

11 Jul 2011

Nurses can help manage S. African's syndemic of TB and HIV

Jason E. Farley, PhD, MPH, CRNP knows the dangers inherent to an increasingly common and hazardous syndemic in South Africa: HIV and drug-resistant tuberculosis.

11 Jul 2011

NewYork-Presbyterian Hospital offers two new treatment options for cancer patients

NewYork-Presbyterian Hospital has two new treatment options for patients with brain tumors and other cancers -- a next-generation radiosurgical Gamma Knife and linear accelerator.

From Elekta 11 Jul 2011

LSUHSC to study mid, long-term health consequences of oil exposure

LSU Health Sciences Center New Orleans School of Public Health is launching the first study ever done of the mid- and long-term health consequences of exposure to oil.

11 Jul 2011

Nature journal publishes landmark genetic study of ovarian cancer

A University of Houston researcher is an author on a landmark multi-institutional genetic study of the most aggressive and common form of ovarian cancer that is published in the current issue of the scientific journal Nature.

11 Jul 2011

Combination therapy shows promise against HER2-positive metastatic breast cancer

Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.

11 Jul 2011

MicroOCT technology can reveal cellular features of coronary artery disease

Researchers at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) have developed a one-micrometer-resolution version of the intravascular imaging technology optical coherence tomography (OCT) that can reveal cellular and subcellular features of coronary artery disease.

11 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

APP receives FDA approval to market Clonidine Hydrochloride Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths.

11 Jul 2011